Muhimbili University College of Health Sciences
Dar es Salaam, Tanzania
NCT Number: NCT00446758
To examine whether daily oral zinc supplementation to HIV-infected Tanzanian preschool children reduces diarrheal and respiratory morbidity, delays HIV disease progression, and improves growth.
Looking for future studies?
Notify Me6 week–60 month
All sexes
Interventional
Phase 3
Dar es Salaam, Tanzania
The purpose of this study is to examine whether daily oral zinc supplementation to HIV-infected Tanzanian preschool children reduces diarrheal and respiratory morbidity, delays HIV disease progression, and improves growth.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Eligible for ART: CD4 cell counts < 20% or above pediatric clinical stage of HIV disease 3 according to WHO staging system.
Severe acute malnutrition; Major congenital malformations
zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children > 12 months.
Time frame: every 4 to 6 months until the end of follow-up
Time frame: every 4 to 6 months until the end of follow-up
Harvard School of Public Health (HSPH)
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05149001
Behavior, Blood-Borne Infections
Aix-en-Provence, France
View Trial DetailsNCT05732675
Behavior, Bisexuality
Ho Chi Minh City, Vietnam
View Trial DetailsNCT07750834
Acquired Immunodeficiency Syndrome, Behavior
Khartoum, Omdurman, Sudan
View Trial DetailsNCT06012136
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Las Vegas, Nevada, United States
View Trial Details